Roux-en-Y Gastric Bypass Surgery in Patients with Polycystic Ovary Syndrome and Metabolic Syndrome

Obesity Surgery

Volumn 26, Issue 1, 2016, Pages 111-118

  Turkmen, Sahruh ^a   Ahangari, Alebtekin ^a   Bäckstrom, Torbjörn ^a  

^a UMEÅ UNIVERSITY   (Sweden)

Author keywords

Allopregnanolone; Metabolic syndrome; Polycystic ovarian syndrome; Progesterone; Roux en Y gastric bypass

Indexed keywords

3ALPHA HYDROXY 5ALPHA PREGNAN 20 ONE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROGESTERONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL; ELTANOLONE;

ADULT; ANOVULATION; ARTICLE; BLOOD SAMPLING; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL EXAMINATION; COMPARATIVE STUDY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DISEASE ASSESSMENT; ECHOGRAPHY; FASTING GLUCOSE; FEMALE; FREE ANDROGEN INDEX; GESTAGEN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HIP CIRCUMFERENCE; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INTERNATIONAL DIABETES FEDERATION CRITERIA; MALE GENITAL TRACT PARAMETERS; MENSTRUAL CYCLE; METABOLIC SYNDROME X; OBESITY; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROGESTERONE BLOOD LEVEL; ROTTERDAM CRITERIA; ROUX EN Y GASTRIC BYPASS SURGERY; STOMACH BYPASS; SYSTOLIC BLOOD PRESSURE; TOTAL OVARIAN VOLUME; WAIST CIRCUMFERENCE; WAIST HIP RATIO; BLOOD; BLOOD PRESSURE; COMPLICATION; MIDDLE AGED; OBESITY, MORBID;

ADULT; BLOOD PRESSURE; CHOLESTEROL, HDL; FEMALE; GASTRIC BYPASS; HUMANS; MENSTRUAL CYCLE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY, MORBID; POLYCYSTIC OVARY SYNDROME; PREGNANOLONE; PROGESTERONE; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE;

EID: 84952985600     PISSN: 09608923     EISSN: 17080428     Source Type: Journal    
DOI: 10.1007/s11695-015-1729-0     Document Type: Article

References (44)

1. Sirmans SM, Pate KA. Epidemiology, diagnosis, and management of polycystic ovary syndrome. Clin Epidemiol. 2013;6:1–13.
2. Spritzer PM. Polycystic ovary syndrome: reviewing diagnosis and management of metabolic disturbances. Arq Bras Endocrinol Metabol. 2014;58:182–7.
3. Escobar-Morreale HF. Polycystic ovary syndrome: treatment strategies and management. Expert Opin Pharmacother. 2008;9:2995–3008.
4. Panidis D, Farmakiotis D, Rousso D, et al. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Fertil Steril. 2008;89:899–906.
5. Vrbikova J, Cifkova R, Jirkovska A, et al. Cardiovascular risk factors in young Czech females with polycystic ovary syndrome. Hum Reprod. 2003;18:980–4.
6. Escobar-Morreale HF, San Millan JL. Abdominal adiposity and the polycystic ovary syndrome. Trends Endocrinol Metab. 2007;18:266–72.
7. Diamanti-Kandarakis E. Role of obesity and adiposity in polycystic ovary syndrome. Int J Obes. 2007;31(2):S8–S13. discussion S31-2.
8. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med. 2006;119:812–9.
9. Vaggopoulos V, Trakakis E, Chrelias C, et al. Comparing classic and newer phenotypes in Greek PCOS women: the prevalence of metabolic syndrome and their association with insulin resistance. J Endocrinol Invest. 2013;36:478–84.
10. Carmina E, Napoli N, Longo RA, et al. Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. Eur J Endocrinol. 2006;154:141–5.
11. Colquitt JL, Picot J, Loveman E, et al. Surgery for obesity. Cochrane Database Syst Rev. 2009;15:CD003641.
12. Malik SM, Traub ML. Defining the role of bariatric surgery in polycystic ovarian syndrome patients. World J Diabetes. 2012;3:71–9.
13. Perez-Torres I, Guarner V, El Hafidi M, et al. Sex hormones, metabolic syndrome and kidney. Curr Top Med Chem. 2011;11:1694–705.
14. Alemany M. Steroid hormones interrelationships in the metabolic syndrome: an introduction to the ponderostat hypothesis. Hormones. 2012;11:272–89.
15. Netjasov AS, Vujovic S, Ivovic M, et al. Relationships between obesity, lipids and fasting glucose in the menopause. Srp Arh Celok Lek. 2013;141:41–7.
16. Golden SH, Kim C, Barrett-Connor E, et al. The association of elective hormone therapy with changes in lipids among glucose intolerant postmenopausal women in the diabetes prevention program. Metabolism. 2013;62:1313–22.
17. Moran LJ, Teede HJ, Noakes M, et al. Sex hormone binding globulin, but not testosterone, is associated with the metabolic syndrome in overweight and obese women with polycystic ovary syndrome. J Endocrinol Invest. 2013;36:1004–10.
18. Prior JC, Elliott TG, Norman E, et al. Progesterone therapy, endothelial function and cardiovascular risk factors: a 3-month randomized, placebo-controlled trial in healthy early postmenopausal women. PLoS One. 2014;9:e84698.
19. Kalkhoff RK. Metabolic effects of progesterone. Am J Obstet Gynecol. 1982;142:735–8.
20. Holmberg E, Backstrom T, Johansson M, et al. Allopregnanolone induces a diurnally dependent hyperphagic effect and alters feeding latency and duration in male Wistar rats. Acta Physiol (Oxf). 2013;208:400–9.
21. Genazzani AD, Strucchi C, Luisi M, et al. Metformin administration modulates neurosteroids secretion in non-obese amenorrhoic patients with polycystic ovary syndrome. Gynecol Endocrinol. 2006;22:36–43.
22. Alberti K, Zimmet P, Shaw J. Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diabet Med. 2006;23:469–80.
23. Rotterdam EA-SPcwg, Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod. 2004;19:41–7.
24. Consultation W. Definition, diagnosis and classification of diabetes mellitus and its complications: Part 1. Diagnosis and classification of diabetes mellitus. Geneva: Wold Health Organization; 1999 [publ. no. WHO/NCD/NCS/99.2].
25. Timby E, Balgard M, Nyberg S, et al. Pharmacokinetic and behavioral effects of allopregnanolone in healthy women. Psychopharmacology (Berl). 2006;186:414–24.
26. Purdy RH, Moore Jr PH, Rao PN, et al. Radioimmunoassay of 3 alpha-hydroxy-5 alpha-pregnan-20-one in rat and human plasma. Steroids. 1990;55:290–6.
27. Toaff R, Toaff ME, Peyser MR. Infertility following wedge resection of the ovaries. Am J Obstet Gynecol. 1976;124:92–6.
28. Legro RS, Dodson WC, Gnatuk CL, et al. Effects of gastric bypass surgery on female reproductive function. J Clin Endocrinol Metab. 2012;97:4540–8.
29. Jamal M, Gunay Y, Capper A, et al. Roux-en-Y gastric bypass ameliorates polycystic ovary syndrome and dramatically improves conception rates: a 9-year analysis. Surg Obes Relat Dis. 2012;8:440–4.
30. Eid GM, Cottam DR, Velcu LM, et al. Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2005;1:77–80.
31. Shirling D, Ashby JP, Baird JD. Effect of progesterone on lipid metabolism in the intact rat. J Endocrinol. 1981;90:285–94.
32. Khokha R, Huff MW, Wolfe BM. Divergent effects of d-norgestrel on the metabolism of rat very low density and low density apolipoprotein B. J Lipid Res. 1986;27:699–705.
33. Chen FP, Lee N, Soong YK. Changes in the lipoprotein profile in postmenopausal women receiving hormone replacement therapy. Effects of natural and synthetic progesterone. J Reprod Med. 1998;43:568–74.
34. Melcangi RC, Panzica GC. Allopregnanolone: state of the art. Prog Neurobiol. 2014;113:1–5.
35. Turkmen SAL, Cengiz Y. Effects of Roux-en-Y gastric bypass surgery on eating behaviour and allopregnanolone levels in obese women with polycystic ovary syndrome. Gynecol Endocrinol. 2014;24:1–5.
36. Turkmen S, Backstrom T, Wahlstrom G, et al. Tolerance to allopregnanolone with focus on the GABA-A receptor. Br J Pharmacol. 2011;162:311–27.
37. Genazzani AD, Chierchia E, Rattighieri E, et al. Metformin administration restores allopregnanolone response to adrenocorticotropic hormone (ACTH) stimulation in overweight hyperinsulinemic patients with PCOS. Gynecol Endocrinol. 2010;26:684–9.
38. Linn ES. Clinical significance of the androgenicity of progestins in hormonal therapy in women. Clin Ther. 1990;12:447–55.
39. Spellacy WN, Buhi WC, Birk SA. Carbohydrate and lipid metabolic studies before and after one year of treatment with ethynodiol diacetate in “normal” women. Fertil Steril. 1976;27:900–4.
40. Spellacy WN, Buhi WC, Birk SA. Prospective studies of carbohydrate metabolism in “normal” women using norgestrel for eighteen months. Fertil Steril. 1981;35:167–71.
41. Coviello AD, Legro RS, Dunaif A. Adolescent girls with polycystic ovary syndrome have an increased risk of the metabolic syndrome associated with increasing androgen levels independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2006;91:492–7.
42. Haffner SM, Kushwaha RS, Foster DM, et al. Studies on the metabolic mechanism of reduced high density lipoproteins during anabolic steroid therapy. Metabolism. 1983;32:413–20.
43. Elbers JM, Asscheman H, Seidell JC, et al. Long-term testosterone administration increases visceral fat in female to male transsexuals. J Clin Endocrinol Metab. 1997;82:2044–7.
44. Lima MM, Pareja JC, Alegre SM, et al. Acute effect of Roux-en-Y gastric bypass on whole-body insulin sensitivity: a study with the euglycemic-hyperinsulinemic clamp. J Clin Endocrinol Metab. 2010;95:3871–5.